Cargando…
How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation
As the UK prepares to leave the EU, it must decide what path it is to take with a large number of regulatory and technical agencies who provide collaboration at the European level. In the case of pharmaceuticals, the European Medicines Agency (EMA) provides pan-European licencing for novel pharmaceu...
Autor principal: | Hatswell, Anthony James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493438/ https://www.ncbi.nlm.nih.gov/pubmed/28717397 http://dx.doi.org/10.3332/ecancer.2017.ed67 |
Ejemplares similares
-
EXITitis in the UK: Gravity Estimates in the Aftermath of Brexit
por: Brakman, Steven, et al.
Publicado: (2023) -
The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018) -
Evaluating the impact of Brexit on the pharmaceutical industry
por: Kazzazi, Fawz, et al.
Publicado: (2017) -
How do we make sense of chaos? Navigating health research regulation through the liminality of the Brexit process
por: Laurie, Graeme
Publicado: (2018) -
Wind of Change: Brexit and European Rehabilitation
por: Villafañe, Jorge Hugo, et al.
Publicado: (2017)